S22G (p.Ser22Gly) variant of EGFR (Epidermal growth factor receptor)
S22G (p.Ser22Gly) in EGFR (Epidermal growth factor receptor) is a missense change. The available variant effect predictions contribute to a CATVariant prioritization score of 0.24 / 1. The record also includes population frequency data, experimental measurements, and structural context.
S22G (p.Ser22Gly) variant details
- p.Ser22Gly
- Ensembl rs2128853486
- Missense
- Variant Prioritization Score for Impact Estimate 0.24
- REVEL 0.10
- MetaLR 0.18
- MetaSVM -0.96
- CADD 13.80
- PolyPhen-2 0.00
- SIFT 0.39
- Population evidence available
- Structural context available
- Dabrafenib and Cetuximab HT-29 cells, base editing z-scores (predicted consequen: score -0.0683